Search filters

Filters
Clear All

Phase

  • 14
  • 13
  • 15
  • 7
  • 13
  • 71
  • 28
  • 1
  • 70

Found 71 Lung Disease trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 1
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
 Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
18 years - 99 years
All genders
Phase 1
Interventional
study of surufatinib in combination with tislelizumab will evaluate the safety, and tolerability in patients with advanced solid tumors.
18 years - 99 years
All genders
Interventional
The goal of this study is to determine the safety and performance of the Edwards EVOQUE System in patients who experience at least moderate tricuspid regurgitation and signs of, or symptoms from or prior heart failure hospitalizations for tricuspid regurgitation.
18 years - 50 years
Female
The purpose of any research study is to answer questions. The MAYFLOWERS study is being done to look at how pregnancy affects the health of women with cystic fibrosis (CF) and to look at the health of babies born to women with CF. It is expected that most but not …
 ENCORE - Study to Evaluate Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
18 years - 99 years
All genders
Phase 3
The purpose of this study is to evaluate the effect and safety of amikacin liposome inhalation suspension (ALIS) study treatment on patient-reported symptoms in subjects newly diagnosed with NTM lung infection caused by MAC who have not started standard treatment. This is an experimental clinical research study, and ALIS is …
 Validation of the prospective registry of outcomes in patients electing lung transplantation (PROPEL)
18 years - 99 years
All genders
The research study is being conducted to develop a test to predict a common complication after lung transplant called primary graft dysfunction (PGD). Predicting PGD before using donor organs may help reduce deaths and improve outcomes of patients receiving a lung transplant in the future.
18 years - 99 years
All genders
Interventional
This research study is being done to investigate if a new technique called ‘needle-based confocal laser endomicroscopy’ (abbreviated as nCLE) is helpful in patients who are undergoing a bronchoscopy to obtain a tissue sample (biopsy) of a lung nodule. The nCLE technique will be used as an addition to the …
 Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
18 years - 99 years
All genders
Phase 1
The primary outcomes will be to establish the safety and feasibility of inhaled imaging in patients with NSCLCand to develop a robust RT planning protocol incorporating both standard of care metrics and those derived from inhaled imaging
 S1900B A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
18 years - 99 years
All genders
Phase 2
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
 Utility of Parametric Response Mapping In Allograft Monitoring After Lung Transplant
18 years - 99 years
All genders
The purpose is to investigate whether parametric response mapping measurements in healthy lung allografts can be used for early detection, prognostication, and phenotyping of CLAD. The target population is bilateral lung transplant recipients who are 6 months post-transplant or later and CLAD free at any of the study institutions. At …